Opko Health has had trading in its common stock halted by The Nasdaq Stock Market, and the exchange has advised OPKO that the halt will continue until the company responds to the exchange’s request for information related to the previously reported lawsuit filed by the SEC against a number of individuals and entities, including OPKO and its CEO and Chairman Phillip Frost. As noted previously, the lawsuit does not contain any allegations about OPKO’s financial practices, financial statements or business practices, and OPKO is confident that once a proper investigation is completed and the facts of the case have been fully disclosed, the matter will be resolved favorably for the company. OPKO is working expeditiously to respond to Nasdaq’s request for information, but it cannot currently estimate when trading will resume.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.